Thermo Fisher Scientific Inc. $TMO Shares Sold by Avalon Trust Co

Avalon Trust Co decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.0% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 35,700 shares of the medical research company’s stock after selling 1,506 shares during the period. Thermo Fisher Scientific comprises 1.1% of Avalon Trust Co’s investment portfolio, making the stock its 25th biggest position. Avalon Trust Co’s holdings in Thermo Fisher Scientific were worth $14,475,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. CBIZ Investment Advisory Services LLC lifted its stake in shares of Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after buying an additional 33 shares in the last quarter. Anderson Financial Strategies LLC acquired a new stake in Thermo Fisher Scientific during the first quarter worth $30,000. Keystone Global Partners LLC acquired a new stake in shares of Thermo Fisher Scientific in the first quarter valued at $31,000. DiNuzzo Private Wealth Inc. increased its position in shares of Thermo Fisher Scientific by 406.7% during the second quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock worth $31,000 after acquiring an additional 61 shares during the period. Finally, HighMark Wealth Management LLC increased its holdings in Thermo Fisher Scientific by 140.6% in the second quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock valued at $31,000 after buying an additional 45 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Thermo Fisher Scientific

In other news, VP Lisa P. Britt sold 10,225 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $571.62, for a total value of $5,844,814.50. Following the transaction, the vice president directly owned 14,145 shares of the company’s stock, valued at $8,085,564.90. This trade represents a 41.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 17,104 shares of the stock in a transaction on Friday, October 24th. The shares were sold at an average price of $573.54, for a total value of $9,809,828.16. Following the completion of the sale, the chief executive officer owned 113,762 shares of the company’s stock, valued at $65,247,057.48. The trade was a 13.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 46,645 shares of company stock worth $25,825,699 over the last ninety days. Insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on TMO shares. Hsbc Global Res cut Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 24th. Argus lifted their price target on shares of Thermo Fisher Scientific from $580.00 to $610.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Citigroup lifted their target price on shares of Thermo Fisher Scientific from $500.00 to $580.00 and gave the stock a “neutral” rating in a research report on Thursday, October 23rd. TD Cowen raised their target price on shares of Thermo Fisher Scientific from $612.00 to $654.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday, October 23rd. Nineteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $601.65.

Thermo Fisher Scientific Stock Up 0.3%

Shares of NYSE:TMO opened at $588.53 on Thursday. The firm has a market cap of $221.12 billion, a PE ratio of 34.00, a price-to-earnings-growth ratio of 3.27 and a beta of 0.82. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97. The company has a fifty day simple moving average of $524.35 and a 200 day simple moving average of $465.87. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping the consensus estimate of $5.50 by $0.29. The company had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business’s revenue was up 4.9% on a year-over-year basis. During the same quarter last year, the firm earned $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has approved a share buyback plan on Thursday, November 6th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to repurchase up to 2.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is 9.94%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.